Cloud Pharmaceuticals awarded Stage I actually grant from NSF SBIR program Cloud Pharmaceuticals, Inc., a therapeutics company centered on cloud-based drug design and development, announced today that it has been awarded a Stage I grant from the National Research Foundation Small Business Innovation Analysis program. The grant is valued at $150,000 suhagra . Cloud Pharmaceuticals designs new medication and drugs candidates and accelerates the advancement process by implementing new, innovative cloud processing technology instead of traditional methods.
Aligned with current FDA and EMA suggestions, the approach ensures that users are able to identify signals in research datasets and will make timely decisions about which sites to focus on for monitoring activities, resulting in reduced regulatory submission risk and costs. This first edition of the net portal aims to put the sponsor in charge in order to run the analysis, set-up the SMART engine, construct and manage data within the operational program, select appropriate statistical assessments and perform the complete CSM process individually and objectively. He proceeds: We are continually attempting to enhance the usability of our answers to meet current sector needs and through discussions with this clients have discovered that many companies want to take complete control of their risk-based monitoring analyses using scientific databases.